Results 111 to 120 of about 9,079 (152)

UBE2M as a bridge spanning neddylation and cell cycle regulation in colorectal adenocarcinoma. [PDF]

Exp Mol Med
Wang Z, Wang Y, Chen Y, Shen H, Lu Y, Tong Y, Xu L, Huang C, Zhang H, Shao Y, Li W, Wang S, Fu Z.   +12 more
europepmc   +1 more source

Disseminated <i>Candida parapsilosis</i> infection complicated by native aortic valve endocarditis and peripheral arterial embolization. [PDF]

Med Mycol Case Rep
Potts CE, Ali A, Pool HC, Ghafoor M.
europepmc   +1 more source

Rare Invasive Fusarium Sinusitis in a Transiently Immunosuppressed Patient. [PDF]

Cureus
Archibald VL, Meenrajan SR, Schain D, Tishena A, Lo MC.   +4 more
europepmc   +1 more source

SIP-SRS Imaging of Cell Wall Synthesis Identifies a Synergy between Micafungin and Amphotericin B. [PDF]

Adv Sci (Weinh)
Zhang M, Zhan Y, Lin H, Chen J, Seleem MN, Mansour M, Cheng JX.   +6 more
europepmc   +1 more source

Deciphering the multidrug resistance paradigm in <i>Candida auris</i>. [PDF]

Antimicrob Agents Chemother
Santana DJ, Cauldron NC, Rogers PD, Cuomo CA.   +3 more
europepmc   +1 more source

Identification of Potential Nontoxic Human <i>BTK</i> Inhibitors through an Integrated Deep Learning and Structure-Based Drug Repositioning Strategy. [PDF]

ACS Omega
Iqbal MW, Sun X, Yuan Q.
europepmc   +1 more source

Quiescence improves Candida albicans survival of fungicidal drug exposure

Imir OB, Druseikis M, Xie Y, Ji Y, Holt L, Berman J, Gresham D.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Micafungin

Annals of Pharmacotherapy, 2004
OBJECTIVE To review the pharmacology, mycology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of micafungin, an echinocandin antifungal agent.
Blair, Jarvis, David P, Figgitt, Lesley J, Scott   +2 more
  +7 more sources